Promoter holding
64.27%
CP
Concept Pharmaceuticals Limited - Due diligence report
A 360° intelligence report on Concept Pharmaceuticals Limited: trust score, financial health, credit view, compliance, directors, growth and…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹349
50% off
New user
Or enjoy up to 50% off with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Concept Pharmaceuticals Limited — 360° Intelligence Report
Generated from MCA filings & public records66/100
Trust Score
Moderate
Concept Pharmaceuticals Limited is assessed as Moderate with a Trust Score of 66/100. Concept Pharmaceuticals Limited is an active public limited indian non-government company incorporated in 1979, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a high compliance risk and low financial risk profile.
Report generated on 03 Jul 2026 from the latest processed filings. Concept Pharmaceuticals Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreModerate
66/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreCaution Indicated
48/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
80/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
60/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreCaution Indicated
45/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
50/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
65/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 60/100 Moderate
- Liabilities ≈ 38% EBITDA - stretched.
- Open charges exceed net worth - secured lenders rank ahead.
- Moderate gearing (D/E 1.42).
- Working-capital cover adequate.
- Profitable - internal accruals available.
- Externally credit-rated (A3).
Charges position: 34 open (280.33 cr) · 19 satisfied (77.95 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Canara Bank | 19 | 48.0 cr |
| Bank Of Baroda | 6 | 48.0 cr |
| Others | 3 | 48.0 cr |
| Dena Bank | 6 | 48.0 cr |
| Industrial Development Bank Of India Limited | 1 | 48.0 cr |
| Oman International Bank | 2 | 48.0 cr |
Compliance Score: 48/100 Caution Indicated
- Company status is Active as per MCA.
- Marked ACTIVE non-compliant (INC-22A).
- Balance sheet slightly behind (Mar 2024).
- Litigation present in 4 court forum(s).
- 13 active GST registration(s).
Legal cases on record (4)
05
Director Intelligence
Stability score: 45/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| REKHA ADHYATMA GUPTA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| YUGIN ADHYATMA GUPTA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VED PARKASH KUMAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 3 directors on the board.
- VED PARKASH KUMAR has DIN status "Deactivated due to non-filing of DIR-3 KYC".
- 1 director exit(s) in the last 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2024)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2024 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
-
Promoters hold a minority stake - exact percentages are part of the full report.
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 50 · Distress 65
Growth signals & trust indicators
Operating for 47+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Profit declined two years in a row.
Compliance score is weak (48/100).
34 open charge(s) registered - assets are encumbered.
4 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence58/100
Review suggested
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- 2 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment63/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 34 open charge(s) of 280.33 cr already registered.
- Compliance gaps should be priced into terms.
Investor view64/100
Mixed indicators
Growth quality and scalability through an investor lens.
- No clear growth signals in the filed years.
- Margin and return trends computable from filings.
- Management churn warrants questions.
09
MCA Filings & Events Timeline
Latest 15 events27 Feb 2025
Charge created
Canara Bank - 49.00 cr
15 Jan 2025
Director appointed
REKHA ADHYATMA GUPTA (Additional Director)
08 Jan 2025
Director ceased
ADHYATMA BANDHU GUPTA
14 Oct 2024
Charge created
Others - 2.50 cr
30 Sep 2024
Last AGM held
Annual general meeting
31 Mar 2024
Latest balance sheet
Filed with ROC
27 Sep 2022
Charge created
The Hongkong And Shanghai Banking Corporation Limited - 3.00 cr
18 Nov 2021
Charge created
Others - 3.73 cr
19 May 2021
Charge satisfied
Canara Bank
12 Mar 2021
Charge created
Canara Bank - 43.00 cr
10 Mar 2021
Charge created
Others - 1.66 cr
07 Feb 2020
Charge satisfied
Bank Of Baroda
03 May 2019
Charge created
Canara Bank - 2.50 cr
30 Mar 2013
Director ceased
YUGIN ADHYATMA GUPTA
01 Nov 2012
Director appointed
YUGIN ADHYATMA GUPTA (Director)
10
Key Observations
Auto-generated from the data aboveRevenue grew 2.1x over the last 4 financial year(s).
Net profit margin moved from 24% to 0.86.
Debt-to-equity stands at 61% - manageable leverage.
Net worth is positive.
3 active director(s) / partner(s); review board churn before relying on management continuity.
13 active GST registration(s) indicate ongoing business operations.
Carries an external credit rating of A3 from Crisil.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a minority stake as per the FY 2024 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
| Company | CIN | Location |
|---|---|---|
| Jagsonpal Pharmaceuticals | L74899DL1978PLC009181 | New Delhi, Delhi, India |
| Axa Parenterals | U24232DL2005PLC148247 | Delhi, Delhi, India |
| Icpa Health Products | U24200MH1983PLC030670 | Mumbai, Maharashtra, India |
| Finecure Pharmaceuticals | U24230GJ2005PLC045724 | Ahmedabad, Gujarat, India |
| Western Drugs | U24232RJ1989PLC004914 | Udaipur, Rajasthan, India |
| Nihon Parkerizing (India) Private Limited | U27100HR2010FTC056081 | Urban Estate, Haryana, India |
| Gracure | U24232DL1992PLC049002 | New Delhi, Delhi, India |
| Vision Products Private Limited | U15140GJ2005PTC045893 | Vadodara, Gujarat, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Concept Pharmaceuticals Limited before audits and certifications: compliance score 48/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Concept Pharmaceuticals Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 60/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Mixed indicators. Growth score 50/100, margin trends, ownership structure and peer set for Concept Pharmaceuticals Limited - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Review suggested. Trust score 66/100, distress signals and MSME payment-delay disclosures - know whether Concept Pharmaceuticals Limited pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (4 case(s) on record), regulatory flags, charge documents trail and director networks for Concept Pharmaceuticals Limited - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Concept Pharmaceuticals Limited an active company?
Concept Pharmaceuticals Limited has MCA status “Active” with a compliance score of 48/100 (Caution Indicated).
Is Concept Pharmaceuticals Limited financially healthy?
Concept Pharmaceuticals Limited has a Financial Health Score of 80/100 (Low Risk) based on its filed financial statements.
Should I do business with Concept Pharmaceuticals Limited?
Its overall Trust Score is 66/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Concept Pharmaceuticals Limited?
Promoters hold a minority stake - exact percentages are in the full report. 3 active director(s) are on record.
Does Concept Pharmaceuticals Limited have loans or charges against its assets?
34 open charge(s) are registered against its assets, and 19 earlier charge(s) stand satisfied.
Is Concept Pharmaceuticals Limited up to date with its ROC filings?
Marked ACTIVE non-compliant (INC-22A). Overall compliance score: 48/100 (Caution Indicated).
Is it risky to lend to Concept Pharmaceuticals Limited?
Its Credit Risk Score is 60/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
